Ani pharmaceuticals reports fourth quarter and full year 2021 results; strong foundation in place to drive sustainable growth

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (nasdaq: anip) (ani or the company) today announced business highlights and financial results for the three and twelve months ended december 31, 2021.   fourth quarter and recent business highlights: received u.s. food and drug administration approval for purified cortrophin™ gel (repository corticotropin injection usp) 80 u/ml, an adrenocorticotropic hormone (acth) indicated for the treatment of certain chronic autoimmune disorders, a
ANIP Ratings Summary
ANIP Quant Ranking